Cooperative Agreement UG3HL169565
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$2.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Cooperative Agreement
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $1,398,792 to the Wake Forest University Health Sciences to serve as the Data Coordinating Center (DCC) for the "Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial" (IMPACT PAD Trial). The DCC will oversee all data-related aspects of this 2x2 factorial randomized...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $1,220,496 Cooperative Agreement under the Cardiovascular Diseases Research (CFDA 93.837) program to Duke University. The award will fund the U.S. portion of the international LEADER-PAD clinical trial, which aims to evaluate the efficacy of low-dose colchicine in reducing the risk of cardiovascular and limb-related events in patients with peripheral artery disease (PAD). The...
This Project Grant award of $660,200.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to investigate the therapeutic potential of carnosine for improving physical function in patients with peripheral arterial disease (PAD). The award aims to evaluate whether carnosine supplementation can enhance muscle function and walking performance in PAD patients, as well as elucidate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $528,179 to the University of Miami to conduct research on improving neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key objectives are to investigate the systemic effects of ischemia training on monocyte reprogramming, determine the role of myeloid cell DHCR24 regulation in...
This Project Grant award for $691,708.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports the development of a novel contrast-free ultrasound-based quantitative angio flow imaging technique to assess peripheral arterial disease (PAD) of the lower limbs. The research project aims to determine the efficacy of this new "Angio Flow Reactivity Analysis" (AFRA) method for assessing PAD in patient...
This $687,517 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the role of the gene Leiomodin 1 (LMOD1) in the formation of mature blood vessels, which is critical for treating peripheral artery disease (PAD). The research aims to determine the mechanism by which reduced LMOD1 expression impairs the maturation of new blood vessels and evaluate whether this...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $3,717,718 Cooperative Agreement to Duke University to conduct the LEADER-PAD clinical trial. The trial aims to evaluate whether low-dose colchicine can reduce the risk of major adverse cardiovascular and limb events in patients with peripheral artery disease (PAD). The 48-month study will enroll 1,000 U.S. participants as part of a larger 6,150-patient...
This Project Grant award of $761,042 from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the mechanisms by which reduced CD73 and its product adenosine contribute to medial arterial calcification (MAC) in peripheral artery disease (PAD). The research aims to 1) determine how the DNA damage response promotes vascular calcification, and 2) investigate how reduced adenosine production alters arginine...
This federal Project Grant award, with a total funding amount of $153,252, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support a 3-year research program focused on elucidating the molecular mechanisms and clinical significance of a specific macrophage population (SPP1+ macrophages) in peripheral arterial disease (PAD). The primary objectives are to determine if SPP1+ macrophages inhibit...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $374,592 to the University of Rochester to conduct research on an electronically-delivered rehabilitation program for patients after hospitalization for acute pulmonary embolism (blood clot in the lungs). The key objectives are to evaluate whether a prescriptive exercise program that gradually intensifies over 8 weeks is more...